PECAM1 and cancer: Then, we found that the frequency of CD31+ or KI67+ cells was not reduced within the tumors by the combined treatment (Fig. 6e, f), suggesting that the synergy was not due to a reduction in tumor vascularization or cancer cell proliferation, respectively.